SHENZHEN, China & ROCKVILLE, Md.–(BUSINESS WIRE)–HighTide Therapeutics Inc. (�HighTide), a clinical-stage biopharmaceutical company with novel treatments for patients with non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that Liping Liu, Founder and Chief Executive Officer, and Adrian M. Di Bisceglie, Chief Medical Officer, will present virtually at the HC Wainwright 4th Annual NASH Conference on Monday, October 5, 2020 at 9:30am EDT.
About HighTide Therapeutics
HighTide Therapeutics Inc. is dedicated to the development of innovative therapeutics for people suffering from non-viral chronic liver diseases, gastrointestinal diseases and metabolic disorders with large and unmet medical needs. HTD1801 is a new molecular entity being developed for the treatment of NASH and PSC. HTD1801 has received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC. For additional information, please visit https://hightidetx.com/.
Contacts
Jeffrey Dao
ir@hightidetx.com
TAIPEI, Taiwan--(BUSINESS WIRE)--#AI--Avril Wu, TrendForce Senior Research Vice President, reports that the HBM market is…
NEW YORK--(BUSINESS WIRE)--Elite, a leading provider of financial management and business operations solutions to the…
KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 6 May 2024 - Shopee Malaysia launches…
NEW TAIPEI CITY, Taiwan--(BUSINESS WIRE)--The SINOX Group will showcase the brand-new technology, the Synlox e-security…
NEW TAIPEI CITY, Taiwan--(BUSINESS WIRE)--With the rise of AI PCs, corresponding security solutions are becoming…
SMEs can achieve higher ROI by maximizing all of Google's products SINGAPORE - Media OutReach…
